Your browser doesn't support javascript.
loading
Hyperimmune bovine colostrum containing lipopolysaccharide antibodies (IMM124-E) has a nondetrimental effect on gut microbial communities in unchallenged mice.
Gore, Rachele; Mohsenipour, Mitra; Wood, Jennifer L; Balasuriya, Gayathri K; Hill-Yardin, Elisa L; Franks, Ashley E.
Afiliação
  • Gore R; Neurodevelopment in Health and Disease Research Program, School of Health and Biomedical Sciences, RMIT University , Bundoora, Victoria, Australia.
  • Mohsenipour M; Department of Microbiology, Anatomy, Physiology and Pharmacology, La Trobe University , Bundoora, Victoria, Australia.
  • Wood JL; Neurodevelopment in Health and Disease Research Program, School of Health and Biomedical Sciences, RMIT University , Bundoora, Victoria, Australia.
  • Balasuriya GK; Department of Microbiology, Anatomy, Physiology and Pharmacology, La Trobe University , Bundoora, Victoria, Australia.
  • Hill-Yardin EL; Department of Physiology and Cell Biology, Kobe University School of Medicine , Kobe, Japan.
  • Franks AE; Neurodevelopment in Health and Disease Research Program, School of Health and Biomedical Sciences, RMIT University , Bundoora, Victoria, Australia.
Infect Immun ; 91(11): e0009723, 2023 Nov 16.
Article em En | MEDLINE | ID: mdl-37830823
Enterotoxigenic Escherichia coli (ETEC) is a leading cause of bacterial diarrhea with the potential to cause long-term gastrointestinal (GI) dysfunction. Preventative treatments for ETEC-induced diarrhea exist, yet the effects of these treatments on GI commensals in healthy individuals are unclear. Whether administration of a prophylactic preventative treatment for ETEC-induced diarrhea causes specific shifts in gut microbial populations in controlled environments is also unknown. Here, we studied the effects of a hyperimmune bovine colostrum (IMM-124E) used in the manufacture of Travelan (AUST L 106709) on GI bacteria in healthy C57BL/6 mice. Using next-generation sequencing, we aimed to test the onset and magnitude of potential changes to the mouse gut microbiome in response to the antidiarrheagenic hyperimmune bovine colostrum product, rich in immunoglobulins against select ETEC strains (Travelan, Immuron Ltd). We show that in mice administered colostrum containing lipopolysaccharide (LPS) antibodies, there was an increased abundance of potentially gut-beneficial bacteria, such as Akkermansia and Desulfovibrio, without disrupting the underlying ecology of the GI tract. Compared to controls, there was no difference in overall weight gain, body or cecal weights, or small intestine length following LPS antibody colostrum supplementation. Overall, dietary supplementation with colostrum containing LPS antibodies produced subtle alterations in the gut bacterial composition of mice. Primarily, Travelan LPS antibody treatment decreased the ratio of Firmicutes/Bacteroidetes in gut microbial populations in unchallenged healthy mice. Further studies are required to examine the effect of Travelan LPS antibody treatment to engineer the microbiome in a diseased state and during recovery.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por Escherichia coli / Escherichia coli Enterotoxigênica / Microbioma Gastrointestinal Idioma: En Revista: Infect Immun Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por Escherichia coli / Escherichia coli Enterotoxigênica / Microbioma Gastrointestinal Idioma: En Revista: Infect Immun Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Austrália